Skip to main content
SpringerLink
Log in
Book cover

CNS Neuroprotection pp 361–386Cite as

Stroke

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 155))

Abstract

The last two decades have witnessed impressive progress in the science of brain ischemia. As other chapters of this monograph document, there is now considerable understanding from animal models of complex pathways and cascades leading to brain injury after cerebral ischemia. Dozens of pharmacological agents have been proven effective in reducing brain injury in animal models. There has also been progress in clinical stroke management. Clinical stroke trials have greatly expanded in patient numbers, and have improved in trial design and experimental endpoints. Several large, well-designed, and clinically meaningful trials have provided advances in primary and secondary stroke prevention. In addition, there is now an effective treatment for patients with acute stroke, tissue plasminogen activator, which improves outcome if given early following stroke onset (NINDS rtPA Stroke Study Group 1995). However, despite substantial effort and expense, no neuroprotective agent has yet been shown to improve clinical outcome in large, randomized multi-center trials. This review examines the data on neuroprotection in clinical stroke, with a focus on future directions for animal and human study.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albers GW, Goldberg MP, Choi DW (1989) N-methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia? Ann Neurol 25:398–403

    Article  PubMed  CAS  Google Scholar 

  • Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM (1995) Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 26:254–258

    Article  PubMed  CAS  Google Scholar 

  • Alberts MJ, Perry A, Dawson DV, Berteis C (1992) Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke 23:352–356

    Article  PubMed  CAS  Google Scholar 

  • American Heart Association (2001) 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association

    Google Scholar 

  • Auer RN, Coupland SG, Jason GW, Archer DP, Payne J, Belzberg AJ, Ohtaki M, Tranmer BI (1996) Postischemic therapy with MK-801 (dizocilpine) in a primate model of transient focal brain ischemia. Mol Chem Neuropathol 29:193–210

    Article  PubMed  CAS  Google Scholar 

  • Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015–1020

    Article  PubMed  CAS  Google Scholar 

  • Barsan WG, Brott TG, Broderick JP, Haley EC Jr, Levy DE, Marler JR (1994) Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. Stroke 25:2132–2137

    Article  PubMed  CAS  Google Scholar 

  • Bogousslavsky J, Regli F (1985) Cerebral infarct in apparent transient ischemic attack. Neurology 35:1501–1503

    Article  PubMed  CAS  Google Scholar 

  • Bordi F, Terron A, Reggiani A (1999) The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats. Eur J Pharmacol 378:153–160

    Article  PubMed  CAS  Google Scholar 

  • Candelise L, Ciccone A (2000) Gangliosides for acute ischaemic stroke. Cochrane Database Syst Rev CD000094

    Google Scholar 

  • Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA (1997) A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 49:671–678

    Article  PubMed  CAS  Google Scholar 

  • Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE (1999a) A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 30:2592–2597

    Article  PubMed  CAS  Google Scholar 

  • Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S (1999b) Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3–5 h after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282:2019–2026

    Article  PubMed  CAS  Google Scholar 

  • Clark WM, Raps EC, Tong DC, Kelly RE (2000) Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 31:1234–1239

    Article  PubMed  CAS  Google Scholar 

  • Cornu C, Boutitie F, Candelise L, Boissel JP, Donnan GA, Hommel M, Jaillard A, Lees KR (2000) Streptokinase in acute ischemic stroke: an individual patient data metaanalysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 31:1555–1560

    Article  PubMed  CAS  Google Scholar 

  • Davis SM, Albers GW, Diener HC, Lees KR, Norris J (1997) Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committed. Lancet 349:32

    Article  PubMed  CAS  Google Scholar 

  • Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J (2000) Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354

    Article  PubMed  CAS  Google Scholar 

  • DeGraba TJ, Pettigrew LC (2000) Why do neuroprotective drugs work in animals but not humans? Neurol Clin 18:475–493

    Article  Google Scholar 

  • del Zoppo GJ, Becker KJ, Hallenbeck JM (2001) Inflammation after stroke: is it harmful? Arch Neurol 58:669–672

    Article  PubMed  Google Scholar 

  • Dewar D, Yam P, McCulloch J (1999) Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 375:41–50

    Article  PubMed  CAS  Google Scholar 

  • Diener HC (1998) Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 8:172–181

    Article  PubMed  CAS  Google Scholar 

  • Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T (2000) Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-h inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31:2543–2551

    Article  PubMed  CAS  Google Scholar 

  • Dorman PJ, Sandercock PA (1996) Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 27:1507–1515

    Article  PubMed  CAS  Google Scholar 

  • Dorman PJ, Counsell C, Sandercock P (1999) Reports of randomized trials in acute stroke, 1955 to 1995. What proportions were commercially sponsored? Stroke 30: 1995–1998

    Article  PubMed  CAS  Google Scholar 

  • Edwards DF (2001) Stroke scales and neurological assessment tools. In: Goldberg MP (ed) Internet Stroke Center website: www.strokecenter.org/trials/scales

    Google Scholar 

  • Fang J, Alderman MH (2001) Trend of stroke hospitalization, united states, 1988–1997. Stroke 32:2221–2226

    Article  PubMed  CAS  Google Scholar 

  • Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J (2000) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane. Database. Syst Rev CD000277

    Google Scholar 

  • Fischman AJ, Alpert NM, Babich JW, Rubin RH (1997) The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 29:923–956

    Article  PubMed  CAS  Google Scholar 

  • Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hantson L, Eriksson B, Lang-Jenssen L, Smakman J (1996) Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 93:56–60

    Article  PubMed  CAS  Google Scholar 

  • Gill R (1994) The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc Brain Metab Rev 6:225–256

    PubMed  CAS  Google Scholar 

  • Ginsberg MD (1996) The validity of rodent brain-ischemia models is self-evident. Arch Neurol 53:1065–1067

    Article  PubMed  CAS  Google Scholar 

  • Goldberg MP (ed) (2001) Stroke Trials Directory. Internet Stroke Center website: www.stroketrials.org

    Google Scholar 

  • Goldberg MP, Weiss JH, Pham PC, Choi DW (1987) N-methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture. J Pharmacol Exp Ther 243:784–791

    PubMed  CAS  Google Scholar 

  • Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC (1999) Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 281:1112–1120

    Article  PubMed  CAS  Google Scholar 

  • Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL, Post-Munson DJ, Signor LJ, Srinivas N,Taber MT,Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, Yeola SW (2001) Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 7:471–477

    Article  PubMed  CAS  Google Scholar 

  • Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 26:602–605

    Article  PubMed  CAS  Google Scholar 

  • Grotta J (1997) Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 28:2338–2346

    Article  PubMed  CAS  Google Scholar 

  • Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251

    Article  PubMed  CAS  Google Scholar 

  • Haley EC Jr (1998) High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. Stroke 29:1256–1257

    Article  PubMed  Google Scholar 

  • Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL (1993) Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res 18:1263–1269

    Article  PubMed  CAS  Google Scholar 

  • Hawkinson JE, Huber KR, Sahota PS, Han HH, Weber E, Whitehouse MJ (1997) The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res 744:227–234

    Article  PubMed  CAS  Google Scholar 

  • Horn J, Limburg M (2000) Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev CD001928

    Google Scholar 

  • Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM (2001) Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 32:2149–2154

    Article  PubMed  CAS  Google Scholar 

  • International Stroke Trial (IST) Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349(9065):1569–1581

    Google Scholar 

  • Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, Brown AN (2001) Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 32:1061–1068

    Article  PubMed  CAS  Google Scholar 

  • Koudstaal PJ, van Gijn J, Lodder J, Frenken WG, Vermeulen M, Franke CL, Hijdra A, Bulens C (1991) Transient ischemic attacks with and without a relevant infarct on computed tomographic scans cannot be distinguished clinically. Dutch Transient Ischemic Attack Study Group. Arch Neurol 48:916–920

    Article  PubMed  CAS  Google Scholar 

  • Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T (1999) Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 340:1781–1787

    Article  PubMed  CAS  Google Scholar 

  • Lago A, Geffner D,Tembl J, Landete L, Valero C, Baquero M (1998) Circadian variation in acute ischemic stroke: a hospital-based study. Stroke 29:1873–1875

    Article  PubMed  CAS  Google Scholar 

  • LaRue LJ, Alter M, Traven ND, Sterman AB, Sobel E, Kleiner J (1988) Acute stroke therapy trials: problems in patient accrual. Stroke 19:950–954

    Article  Google Scholar 

  • Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399 [Suppl 6738]:A7–A14

    Article  Google Scholar 

  • Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J (2000) Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355:1949–1954

    Article  PubMed  CAS  Google Scholar 

  • Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T (2001) Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32:675–680

    Article  PubMed  CAS  Google Scholar 

  • Lenzi GL, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton JD, Carolei A, Dorsey FC, Rocca WA, Bruno R (1994) Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial. Stroke 25: 1552–1558

    Article  PubMed  CAS  Google Scholar 

  • Levy DE (1988) How transient are transient ischemic attacks? Neurology 38:674–677

    Article  PubMed  CAS  Google Scholar 

  • Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T (2001) The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. Neurology 57:1199–1205

    Article  PubMed  CAS  Google Scholar 

  • McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP (1998) Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 4:291–297

    Article  PubMed  CAS  Google Scholar 

  • Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S (2000) Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. Stroke 31:2585–2590

    Article  PubMed  CAS  Google Scholar 

  • Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF (1999) Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg 91:737–743

    Article  PubMed  CAS  Google Scholar 

  • Muir KW, Hamilton SJ, Lunnon MW, Hobbiger S, Lees KR (1998) Safety and tolerability of 619C89 after acute stroke. Cerebrovasc Dis 8:31–37

    Article  PubMed  CAS  Google Scholar 

  • National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587

    Google Scholar 

  • North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325:445–453

    Google Scholar 

  • Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, Yasuhara H (1999) Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 9:112–118

    Article  PubMed  CAS  Google Scholar 

  • Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244:1360–1362

    Article  PubMed  CAS  Google Scholar 

  • Ortiz GG, Guerrero JM, Reiter RJ, Poeggeler BH, Bitzer-Quintero OK, Feria-Velasco A (1999) Neurotoxicity of dextrorphan. Arch Med Res 30:125–127

    Article  PubMed  CAS  Google Scholar 

  • RANTTAS Investigators (1996) A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 27:1453–1458

    Google Scholar 

  • Ricci S, Celani MG, Cantisani TA, Righetti E (2000) Piracetam in acute stroke: a systematic review. J Neurol 247:263–266

    Article  PubMed  CAS  Google Scholar 

  • Rothman SM, Thurston JH, Hauhart RE, Clark GD, Solomon JS (1987) Ketamine protects hippocampal neurons from anoxia in vitro. Neuroscience 21:673–678

    Article  PubMed  CAS  Google Scholar 

  • Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL (2001) Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285:1719–1728

    Article  PubMed  CAS  Google Scholar 

  • Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC (1999) Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke 30:293–298

    Article  PubMed  CAS  Google Scholar 

  • Samsa GP, Matchar DB (2001) Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 32:669–674

    Article  PubMed  CAS  Google Scholar 

  • Steinberg GK, Bell TE, Yenari MA (1996) Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg 84:860–866

    Article  PubMed  CAS  Google Scholar 

  • Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752–2758

    Google Scholar 

  • Stroke Therapy Academic Industry Roundtable (STAIR) II (2001) Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32:1598–1606

    Google Scholar 

  • Stys PK (1998) Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab 18:2–25

    Article  PubMed  CAS  Google Scholar 

  • Tekkok SB, Goldberg MP (2001) AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci 21:4237–4248

    PubMed  CAS  Google Scholar 

  • Tirilazad International Steering Committee (2000) Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 31:2257–2265

    Google Scholar 

  • Tymianski M, Spigelman I, Zhang L, Carlen PL, Tator CH, Charlton MP, Wallace MC (1994) Mechanism of action and persistence of neuroprotection by cell-permeant Ca2+ chelators. J Cereb Blood Flow Metab 14:911–923

    Article  PubMed  CAS  Google Scholar 

  • Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T, Claesson L (1999) Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 30:21–28

    Article  PubMed  CAS  Google Scholar 

  • Wester P, Radberg J, Lundgren B, Peltonen M (1999) Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: a prospective, multicenter study Seek- Medical-Attention-in-Time Study Group. Stroke 30:40–48

    Article  PubMed  CAS  Google Scholar 

  • Wiebers DO, Adams HP Jr, Whisnant JP (1990) Animal models of stroke: are they relevant to human disease? Stroke 21:1–3

    Article  PubMed  CAS  Google Scholar 

  • Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco RL, Whisnant JP (1999) Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30:1991–1994

    Article  PubMed  CAS  Google Scholar 

  • Wroe SJ, Sandercock P, Bamford J, Dennis M, Slattery J, Warlow C (1992) Diurnal variation in incidence of stroke: Oxfordshire community stroke project. BMJ 304:155–157

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H (1998) Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29:12–17

    Article  PubMed  CAS  Google Scholar 

  • Zivin JA, Grotta JC (1990) Animal stroke models. They are relevant to human disease. Stroke 21:981–983

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. P. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA

    Frank W. Marcoux (Vice President, Biology) (Vice President, Biology)

  2. Department of Neurology Box 8111, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA

    Dennis W. Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldberg, M.P. (2002). Stroke. In: Marcoux, F.W., Choi, D.W. (eds) CNS Neuroprotection. Handbook of Experimental Pharmacology, vol 155. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06274-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-06274-6_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-07625-1

  • Online ISBN: 978-3-662-06274-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation